Experimental stem cell transplant could reduce toxic side effects for fanconi anemia patients

NCT ID NCT04784052

Recruiting now Disease control Sponsor: Porteus, Matthew, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new way to treat Fanconi Anemia, a rare genetic disorder that causes bone marrow failure. Doctors will give patients donor stem cells that have been specially filtered to remove certain immune cells, along with an experimental antibody called JSP191. The goal is to help the new cells grow and rebuild the blood system with fewer severe side effects than standard chemotherapy. The trial is recruiting 18 participants and will follow them for up to 2 years after the transplant.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FANCONI ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Fanconi anemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FANCONI ANEMIA

Contacts and locations

Show contact details

Locations

Stanford University
RECRUITING

Stanford, California, 94305, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••